Par Drugs And Chemicals Limited has informed the Exchange regarding Appointment of Ms Maulin Shah & Associates as Other of the company w.e.f. April 01, 2025.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Par Drugs and Chemicals informed the exchange about the outcome of its board meeting held on August 29, 2025. The board fixed the 26th Annual General Meeting for September 27, 2025 in Vadodara and approved the AGM notice, e-voting (September 23–26, 2025), and book closure (September 20–27, 2025). It appointed M/s. Sarupria Somani & Associates as Statutory Auditor for FY 2025-26 at ₹2.25 lakh, re-appointed M/s. Siddhpura & Co as Internal Auditor, re-appointed M/s DG Patel & Associates as Secretarial Auditor for five years (FY 2025-26 to FY 2029-30), and appointed M/s Maulin Shah & Associates as Cost Auditor for FY 2025-26 at ₹60,000. The board also approved the re-appointment of Managing Director Mr. Falgun Savani (by rotation), Independent Director Mrs. Bintal Shah for a second five-year term, and ₹24 lakh annual remuneration for Independent Director Mr. Pravin Bhayani. Additionally, it cleared the purchase of a Tata Harrier (about ₹29.30 lakh) for CEO and Director Mr. Jignesh Savani.
These are largely routine, AGM-related housekeeping decisions (auditor appointments and director re-appointments), which should not materially affect the stock price. The vehicle purchase for the CEO is a small, one-time expense relative to company operations.